American Academy of Family Physicians

Printer-friendly version

Share this on AAFP Connection

Share this page

FDA Finds Yet More ED Agents Unsafe

'Blue Steel,' 'Hero' Join Long List of Hazardous 'Supplements' for Men

By Jessica Pupillo

The FDA has added two additional "dietary supplements" to its list of unapproved drugs being sold to treat erectile dysfunction, or ED.

FDA Advisory
Consumers are being warned not to purchase or use "Blue Steel" and "Hero," distributed by Active Nutraceuticals or the Marion Group in Carrollton, Ga., according to a March 25 FDA news release. The products are considered illegal drugs because they have not been proven safe or effective and because they contain undeclared ingredients, including substances similar in chemical structure to sildenafil, the FDA found.

Sildenafil is the active ingredient in prescription drugs for ED. The similar compound found in Blue Steel and Hero may interact with nitrate-containing prescription medications, such as nitroglycerin, commonly prescribed to control symptoms associated with diabetes, high blood pressure, high cholesterol or heart disease. ED is common in men with these medical conditions, the release said.

"Because they may have been advised against taking ED drugs, these men may seek products like Blue Steel or Hero because the products are marketed as 'all natural' or as not containing the active ingredients in approved ED drugs," the FDA statement warned.

Previously, the FDA has warned of the dangers of 25 other unsafe products marketed as treatments for ED or sexual enhancement and available for sale online. The FDA now provides a clearinghouse of information on these dangerous ED products. Each of these products contains either undeclared ingredients; prescription drug ingredients, including sildenafil or vardenafil (the active ingredient in Levitra); or analogs of the active ingredients in these two prescription drugs.

In addition to asking patients to avoid these ED products, physicians are encouraged to report adverse events to MedWatch by calling (800) FDA-1088 or via the MedWatch Web site.

The number of such problematic products available online is increasing, according to the FDA. The popularity of and potential dangers posed by these products underscore the importance of talking with patients about any complementary or alternative therapies they use.

To that end, free materials are available for doctors and consumers through the "Time to Talk" campaign sponsored by the National Center for Complementary and Alternative Medicine, or NCCAM. Among other resources, this NCCAM initiative provides toolkits designed to help prompt discussion on the use of alternative medicines.

Share this on AAFP Connection

Health of the Public

Study: PPI Does Not Routinely Improve Asthma Control

Recalled Oral Contraceptives Pose Pregnancy Risk

CDC to Fund 2D Vaccine Barcoding Pilot

2012 Immunization Schedules Reflect Multiple Changes

Study: Cognitive Decline Detected in Middle-aged Adults

CDC Toolkit Can Help Clinicians Fight Norovirus Infection

Patient-Centered Care Linked to Lower Mortality

Study: Inappropriate Cancer Screenings Continue

Novartis Manufacturing Plant Closes After Drug Mix-ups

FDA Announces Classwide REMS for TIRF Medications

New Infants' Acetaminophen Products Hit Store Shelves

Avoid Environmental Factors Linked to Breast Cancer

Risk for Thrombosis Prompts REMS for Rivaroxaban

Common Drugs Implicated in Most Emergency Hospitalizations

CDC Launches Campaign for Child Medication Safety

HHS Blocks Expanded OTC Access to Plan B

Push Is On to Vaccinate Pregnant, Postpartum Women

FDA Committee Votes to Broaden PCV13 Indication

AAFP Foundation Program Aims to Fight Chronic Disease

NIAAA Alcohol Screening Guide Targets Teens

Walgreens, AAFP Launch Flu Vaccine Pilot in Five States

Helping Patients Quit Smoking Starts With a Question

Trilipix Efficacy in Question, Says FDA

USPSTF Addresses Skin Cancer, Obesity, Cervical Cancer Screening

AAFP Endorses ACP Guideline on ED

ACIP Recommends Expanded HPV, Hepatitis B Vaccination

Bacterial Contamination Spurs Nasal Spray Recall

CDC Renews Call for PCV13 Vaccination

USPSTF Recommends Against PSA Screening

AAFP Supports HHS' Million Hearts Initiative

FDA Phases Out Primatene Mist Inhalers

AHRQ Guides Explain Benefits, Risks of GERD Treatments

Tar Wars Winner Gives Back

Office Champions Project Nets Smoking Cessation Gains

Multiple Lots of Oral Contraceptives Recalled

New Vaccine Review Finds Few Adverse Events

HPV Vaccination Rates Still Lag, Says CDC

Renal Injury Prompts Reclast Label Changes

High-dose Citalopram Linked to Abnormal Heart Rhythms

AHRQ Sleep Apnea Guides Review Diagnosis, Management

Board Chair Spotlights Breadth of Family Medicine Training

USPSTF Softens Stance on Bladder Cancer Screening

HHS Expands Coverage for Women's Preventive Services

Teledermatology Project Aids Underserved Patients

New Chantix Warnings Cite Cardiovascular Risk

Pertussis Outbreaks Lead to CDC Alert on PCR Testing